Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vitrolife ABCHIX:VITRS 77 Return-on-Tangible-Asset is 17.33% as of Jun. 2026, which is 13% below its 10-year median of 19.87. GuruFocus rates CHIX:VITRS with a GF Score™ of 77/100 and a GF Value™ of kr185.92. The stock has 6 warning signs investors should review. Among 854 Medical Devices & Instruments companies, Vitrolife AB ranks worse than 94.26% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Vitrolife AB's annualizedNet Income for the quarter that ended in Jun. 2026 was kr516 Mil. Vitrolife AB's average total tangible assets for the quarter that ended in Jun. 2026 was kr2,977 Mil. Therefore, Vitrolife AB's annualized Return-on-Tangible-Asset for the quarter that ended in Jun. 2026 was 17.33%.
The historical rank and industry rank for Vitrolife AB's Return-on-Tangible-Asset or its related term are showing as below:
CHIX:VITRs'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -172.88 Med: 19.87 Max: 37.23
Current: -170.24
During the past 13 years, Vitrolife AB's highest Return-on-Tangible-Asset was 37.23%. The lowest was -172.88%. And the median was 19.87%.
CHIX:VITRs's Return-on-Tangible-Asset is ranked worse than 94.26% of 854
companies
in the Medical Devices & Instruments industry
Industry Median: 0.665
vs CHIX:VITRs: -170.24
Vitrolife AB (CHIX:VITRs) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Vitrolife AB Return-on-Tangible-Asset Related Terms
Vitrolife AB Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Vitrolife AB's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:VITRS vs ABT, SYK, MDT: Return-on-Tangible-Asset Comparison
For the Medical Devices subindustry, Vitrolife AB's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitrolife AB Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vitrolife AB's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Vitrolife AB's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Jun. 2026) net income data.
What does a Return-on-Tangible-Asset of 17.33% mean?
Vitrolife AB (CHIX:VITRS) has a Return-on-Tangible-Asset of 17.33% as of Jun. 2026. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Vitrolife AB and its competitors. This is 13% below median its historical median of 19.87. According to the industry distribution chart, Vitrolife AB ranks #805 out of 854 companies in the Medical Devices & Instruments industry, placing it in the top 94.3%.
Is Vitrolife AB's Return-on-Tangible-Asset too high?
Vitrolife AB's current Return-on-Tangible-Asset of 17.33% is 13% below median its 10-year median of 19.87. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.67. Vitrolife AB's value of 17.33% is 2506% above this industry median. Based on the distribution chart, Vitrolife AB ranks #805 out of 854 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Vitrolife AB has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Vitrolife AB's Return-on-Tangible-Asset compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Vitrolife AB ranks #805 out of 854 companies for Return-on-Tangible-Asset. This places Vitrolife AB in the lower half of its industry. The industry median Return-on-Tangible-Asset is 0.67. Vitrolife AB's value of 17.33% is 2506% above this benchmark. While the company's 10-year median is 19.87 vs. the industry median of 0.67, Vitrolife AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.67, based on 854 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vitrolife AB's current Return-on-Tangible-Asset of 17.33% is 2506% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Vitrolife AB and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.67 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitrolife AB's current Return-on-Tangible-Asset is 17.33%, which is 13% below median its own 10-year median of 19.87. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrolife AB stock overvalued right now?
Vitrolife AB (CHIX:VITRS) has a current Return-on-Tangible-Asset of 17.33%. The stock's GF Value™ is kr185.92, compared to a current price of kr105.75 — trading 43.1% below its estimated fair value. The current Return-on-Tangible-Asset is 17.33%, which is 13% below median its 10-year median of 19.87 and 2506% above the Medical Devices & Instruments industry median of 0.67. Vitrolife AB's overall GF Score™ is 77/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Vitrolife AB (CHIX:VITRS), the current Return-on-Tangible-Asset is 17.33% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vitrolife AB (CHIX:VITRS) Overvalued in 2026?
Based on GuruFocus' analysis, Vitrolife AB stock appears to be undervalued.
The current stock price of kr105.75 is trading 43.1% below its estimated GF Value™ of kr185.92.
Key valuation signals for CHIX:VITRS:
Return-on-Tangible-Asset: 17.33% (13% below median its 10-year median of 19.87)
GF Value™: kr185.92 vs. price of kr105.75 (43.1% below fair value)
Industry Position: 2506% above the Medical Devices & Instruments median (#805 of 854)
No single metric tells the full story. See the CHIX:VITRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The company has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.
77GF Score
Get the complete analysis for CHIX:VITRS
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:VITRS has been successfully added to your 
